Under the loan facility, whose amount was not disclosed, the company received initial funding and a conditional option to receive additional funding.
Femasys will use the funds for working capital as it supports the advancement of its device.
Led by Kathy Lee-Sepsick, President & CEO, Femasys is advancing non-surgical female sterilization medical devices.Its FemBloc™ Permanent Contraceptive System allows physicians to deliver a biomaterial through a catheter based system. Its two commercially available products include a device for diagnosis of infertility (FemVue® Saline-Air device) and a sampler for cervical cancer (FemCerv® Endocervical Sampler).
30/04/2015: Femasys Raises $10.2M in Financing